ModifiedUnitedHealthcarePolicy CS036TN.X

Electrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Tennessee Only)

Medical policy governing coverage and medical necessity of various electrical stimulation modalities (e.g., TENS, NMES, PENS, FES, implanted neurostimulation) for Tennessee Medicaid and CoverKids members.

Policy Summary

PayerUnitedHealthcare

PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Tennessee Only)

Policy CodePolicy CS036TN.X

Change TypeUpdated clinical evidence, device and references

Effective DateMar 1, 2025

Next Review Date

Key ActionObtain prior authorization and document prior conservative therapy and indication-specific objective measures when requesting implantable or extended electrical stimulation therapies.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.

Updated reference link to the TennCare Medicaid, Chapter 1200-13-13-.10: Exclusions.

Tennesseepolicy application

20+studies cited

46RCTs in NMES swallowing review

240ReActiv8 RCT n

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

state exclusion cited

Coverage and Medical Necessity Criteria

NMES Medical Necessity

NMES is proven and medically necessary for the following when ALL criteria for each indication are met:

NMES covered indications: Disuse muscle atrophy: nerve supply to the muscle is intact AND atrophy is not of neurological origin (e.g., due to casting, splinting, contracture).

NMES indicated only when nerve supply intact and cause is non-neurologic.

Post‑operative lower limb rehabilitation (TKA): Used as part of a comprehensive lower limb rehabilitation program following total knee arthroplasty (NMES provided in addition to standard rehabilitation).

NMES coverage requires use as adjunct to comprehensive rehab program.

Post‑stroke upper extremity motor recovery: To improve upper extremity function in persons with partial paralysis after stroke when NMES is used as part of a comprehensive rehabilitation program (not as a standalone replacement for standard rehab).

NMES coverage limited to adjunctive use within comprehensive stroke rehabilitation.

TENS Medical Necessity

TENS coverage summary:

TENS is proven and medically necessary in certain circumstances; specific medical necessity clinical coverage criteria and patient eligibility should be determined using InterQual CP: Durable Medical Equipment, Transcutaneous Electrical Nerve Stimulation (TENS) and by referencing TennCare Medicaid Chapter 1200-13-13-.10 exclusions.

Policy defers to InterQual and TennCare exclusion rules for detailed TENS criteria.

Unproven / Not Medically Necessary

The following modalities are unproven and not medically necessary due to insufficient evidence of efficacy:

Unproven / Not Medically Necessary modalities: Interferential therapy (IFT); Microcurrent electrical nerve stimulation (MENS); Percutaneous electrical nerve stimulation (PENS)/percutaneous neuromodulation therapy (PNT); Percutaneous electrical nerve field stimulation (PENFS); Percutaneous peripheral nerve stimulation (PNS); Peripheral subcutaneous field stimulation (PSFS)/peripheral nerve field stimulation (PNFS); Pulsed electrical stimulation (PES); Restorative neurostimulation; Scrambler therapy (ST); Translingual stimulation (TS) for gait rehabilitation.

Listed modalities considered unproven and not medically necessary when requested outside indications supported by sufficient evidence.

Modality descriptions and evidence summaries

Evidence summaries and clinical positioning for multiple electrical stimulation modalities

PES/PES hypothesis: Pulsed electrical stimulation (PES) is described as a mechanistic modality hypothesized to facilitate bone and cartilage repair and to alter inflammatory cell function; current evidence is mechanistic and insufficient to establish routine clinical efficacy for pain or tissue healing.

Mechanistic rationale presented; clinical evidence insufficient.

Restorative neurostimulation (ReActiv8) description: Restorative neurostimulation is an implantable approach that stimulates lumbar multifidus (e.g., ReActiv8) intended to rehabilitate neuromuscular control in mechanical chronic low back pain; trials and evidence assessments are cited but limitations (attrition, small samples) are noted.

Device-level description and evidence context provided.

Scrambler Therapy (ST) description: Scrambler therapy is a noninvasive transdermal treatment applying variable nonlinear waveforms to dermatomes aiming to provide 'non-pain' information to reduce chronic pain; available studies are small and heterogeneous.

Indication-specific evidence summaries

Summaries of clinical trials and systematic reviews indicate NMES may be considered when used as an adjunct to conventional therapy for specific indications with demonstrated outcome improvements:

Post‑stroke dysphagia (NMES + swallowing therapy): Systematic reviews and multiple RCTs (e.g., 46 RCTs pooled, ~3,346 participants) report that NMES combined with swallowing therapy can improve swallowing function and QOL in post‑stroke dysphagia; treatment courses in trials ranged from 2 to 12 weeks.treatment course 2-12 weeks reported

Evidence quality limited by heterogeneity and geographic concentration.

Post‑stroke motor recovery (upper/lower extremity): Multiple RCTs and meta‑analyses report modest improvements in motor outcomes and ADLs when NMES or contralaterally controlled FES is applied as part of subacute rehabilitation, with common protocols of 3–12 weeks and session durations such as 20–30 minutes/day several times per week.varied; examples 20-30 min/day, 3-7x/week

Some trials show CCFES may outperform cyclic NMES for manual dexterity.

Evidence-derived coverage considerations

Evidence and conclusions reported in the cited reviews and trials indicate the following coverage-relevant stances:

NMES for hospitalized/ICU patients: Some RCTs and meta‑analyses report small‑to‑moderate improvements in muscle strength, muscle size, walking performance, and reduced ventilation time in ICU populations; overall evidence is heterogeneous and of low to moderate quality.evidence variable

Examples: systematic reviews and RCTs cited for ICU and postsurgical populations.

NMES for COPD: Cochrane and other reviews found NMES can increase quadriceps force and endurance and improve 6‑minute walk distance when applied alone, but evidence quality is low/very low and NMES should not replace standard pulmonary rehabilitation.evidence low

Hill et al. Cochrane review referenced.

NMES for dysphagia: Systematic reviews conclude current evidence is limited; NICE recommends further research and use only with special arrangements for governance and audit for transcutaneous NMES for dysphagia.

Modalities coverage summary

Coverage stance informed by available evidence and guidelines

IFT/IFC: Interferential therapy (IFT/IFC) shows inconsistent short‑term benefit in some meta‑analyses but no clear long‑term advantage; NICE recommends against offering IFT for knee osteoarthritis, chronic primary pain, and low back pain with/without sciatica, supporting a not‑recommended or investigational coverage stance in those settings.

Local guideline alignment may determine coverage application.

MENS/MCT: Microcurrent (MENS/MCT) RCTs/meta‑analyses report modest short‑term pain reductions for selected conditions but overall evidence is limited and heterogeneous, supporting investigational or limited coverage only with strong justification.

Small trials and inconsistent outcomes limit general coverage.

PENS/TEAS/TENS summary: PENS and TEAS demonstrate immediate to short‑term reductions in pain and opioid consumption in perioperative and some musculoskeletal settings; heterogeneity and lack of durable long‑term data limit routine coverage for chronic indications, though perioperative adjunctive use may be reasonable with documentation of short‑term outcomes.

Evidence considerations for coverage decisions

Evidence-informed considerations derived from trials and guidelines in these sections

Short‑term benefit evidence: Randomized trials and meta‑analyses often report short‑term reductions in pain and some functional improvements with TEAS/PENS and related modalities; however, these benefits are typically immediate to weeks in duration and long‑term durability is not established.

Most trials measure immediate or short‑term endpoints; long‑term efficacy uncertain.

Evidence limitations: Many studies are small, single‑center, heterogeneous in stimulation parameters, and lack long‑term follow‑up; systematic reviews grade evidence quality as low to very low for many indications, which should inform conservative coverage and documentation expectations.

Guidelines (NICE, AAOS) emphasize limited evidence and recommend conservative‑first approaches.

Indications with more supportive data: TEAS has consistent RCT/meta‑analytic support for short‑term postoperative pain reduction and reduced opioid use; PENFS has multiple pediatric studies showing symptom improvements in DGBIs when patients have failed prior therapies; where evidence is stronger, conditional coverage with documentation of prior therapy failure and planned outcome measurement may be considered.

PENFS — conditional coverage considerations

PENFS has multiple small RCTs and observational studies supporting short-term symptom improvement in pediatric DGBIs/IBS; coverage stance depends on demonstrated prior therapy failure and documentation of diagnostic criteria and outcome measurement.

PENFS conditional coverage criteria: Patient meets diagnostic criteria for disorders of gut–brain interaction (DGBI)/IBS per Rome III/IV AND has documented failure of multiple (often ≥3–4) pharmacologic and conservative therapies AND baseline validated symptom measures (e.g., API, NSS, PFSD, FDI) are provided with a plan for serial outcome assessments during and after PENFS therapy.

Reflects trial and registry inclusion criteria and common study practice.

PNS — conditional/experimental considerations

Percutaneous PNS has low‑to‑very‑low quality evidence with some RCTs and case series showing clinically meaningful pain and functional improvements for select indications.

PNS conditional/experimental considerations: Percutaneous PNS may be considered for chronic, refractory peripheral or postsurgical neuropathic pain when patients have failed comprehensive conservative management and when multidisciplinary evaluation supports PNS; documentation should include prior conservative treatments, pain scores, functional impairment, rationale for PNS, and planned treatment duration (many trials used up to 60-day lead placements).

Reflects trial protocols (e.g., 60-day treatments) and evidence uncertainty.

PES/PEMF — not established

PES/PEMF evidence is insufficient to support use for chronic pain.

PES/PEMF not established: Available studies on pulsed electromagnetic field (PEMF) or pulsed electrical stimulation (PES) are limited, often small or retrospective, and do not provide adequate evidence to support routine coverage for chronic pain indications; requests require strong supporting justification and may be considered experimental.

Öztürk et al. and systematic reviews note insufficient evidence.

Evidence-based coverage considerations

Summary of coverage-relevant evidence-based considerations

Evidence gaps and prerequisites: For PNS, PES/PEMF, and restorative neurostimulation, published studies are often small, heterogeneous, and at risk of bias; coverage decisions should consider these evidence gaps and generally require documentation of prior conservative care and clear rationale for device selection.

ECRI, Hayes and other HTAs characterize evidence as limited or inconclusive.

Conservative therapy requirement: Restorative neurostimulation trials typically enrolled patients who had failed conventional management including ≥90 days of medical management and at least one course of physical therapy; documentation of such conservative care is reasonable prior to approval for implantable restorative devices.>90 days

Derived from ReActiv8 trial inclusion criteria.

Device‑specific stance: PNS: limited and heterogeneous data; PES/PEMF: insufficient evidence despite some small positive studies; Restorative neurostimulation: some sustained improvements reported but evidence limited by attrition and small samples — additional independent, larger RCTs recommended before broad coverage.

Restorative Neurostimulation (ReActiv8) — evidence summary

Evidence and limitations summarized from RCTs and single-arm studies

ReActiv8 RCT evidence: A randomized, double‑blinded, sham‑controlled trial (Gilligan et al. 2021) in participants with refractory mechanical CLBP reported clinically meaningful improvements (e.g., 64% had ≥50% improvement) but reviewers noted limitations and some endpoints at 120 days were of uncertain clinical importance; infections and explants were reported in follow‑up.

RCT and trial adverse events and explant data highlighted.

Single‑arm and long‑term data: Prospective single‑arm studies and long‑term follow‑up reports show sustained improvements for subsets of participants but are limited by small samples, high attrition, lack of independent controls, and risk of bias.

Mitchell et al. 4‑year follow‑up and Gilligan 3–5 year follow‑ups referenced.

Overall evidence limitations: ECRI and other reviewers concluded evidence is inconclusive due to small study sizes, high risk of bias, loss to follow‑up and heterogeneity; additional independent studies are recommended before broader coverage expansion.

Recommendation for more independent, higher‑quality trials.

Scrambler Therapy (ST) — evidence summary

Summaries of randomized trials, single‑arm studies, meta‑analyses and guideline positions

RCT and meta‑analysis findings for Scrambler Therapy: Meta‑analyses and RCTs report marginal or inconsistent reductions in pain with scrambler therapy; some subgroup analyses show reduced analgesic consumption, but overall evidence quality is low and heterogeneous.

Jin et al. 2022 and other systematic reviews report small trials and mixed results.

Pilot and small RCT results: Multiple small RCTs and single‑arm studies report short‑term improvements in pain and function for neuropathic conditions (e.g., CIPN, post‑burn neuropathic pain), but studies are limited by small sample sizes, short follow‑up, and potential industry bias.

Guideline bodies (ASCO, ESMO) do not recommend routine use outside trials for CIPN.

Guideline and evidence limitations: Systematic reviews and guideline statements conclude that overall evidence is low/very‑low quality and insufficient to support general recommendation of scrambler therapy outside research settings.

ESMO gives a D rating for CIPN; ASCO recommends further research.

Translingual Stimulation (PoNS/TLNS) — evidence summary

Evidence from RCTs, pilot studies, and ECRI assessment for balance/gait disorders

Controlled trials for PoNS/TLNS: ECRI reviewed 3 RCTs and 1 nonrandomized controlled study and found evidence inconclusive due to limited data; some RCTs report improvements in gait and balance when PoNS is combined with targeted physical therapy (e.g., multicenter RCT by Ptito et al. 2021).

Trials often combined TLNS with supervised PT and enrolled participants after plateau in recovery.

Pilot/mechanistic studies: Pilot RCTs (Tyler 2014; Leonard 2017) reported greater improvements in gait/balance with active PoNS plus PT versus control, and some studies reported neuroimaging changes; however, sample sizes were small and generalizability limited.

Evidence suggests potential adjunctive benefit but requires confirmation.

Evidence limitations and recommendation: Limitations include small samples, single research centers, heterogeneity of prior therapies, and potential developer‑center bias; larger independent trials are recommended before routine coverage expansion.

ECRI recommended further independent studies.

Device-specific evidence and indications

TLNS/PoNS clinical findings: Randomized trials (Ptito et al. 2021; Tyler et al. 2019) reported that TLNS combined with targeted physical therapy improved balance and gait in patients with chronic deficits after mmTBI or MS; improvements occurred in both active and control frequency groups in some trials and were sustained after treatment discontinuation in selected measures.

Trials enrolled patients who had plateaued with prior PT and used device logs to monitor adherence.

ReActiv8 device indication: ReActiv8 received PMA for bilateral stimulation of the L2 medial branch to manage intractable chronic low back pain associated with multifidus dysfunction in adults who have failed conservative therapy including medications and physical therapy and who are not candidates for spine surgery; imaging or physiologic testing may be used to document multifidus dysfunction.

Device labeling and FDA PMA referenced for indication specifics.

This policy applies to Tennessee Medicaid (TennCare) and CoverKids members and supplements plan-specific benefit rules. For TENS medical necessity criteria, the policy defers to InterQual® CP: Durable Medical Equipment, Transcutaneous Electrical Nerve Stimulation (TENS) and to the TennCare Medicaid Chapter 1200-13-13-.10 exclusions for any state-specific limits. UnitedHealthcare may also use third-party tools (e.g., InterQual) to assist in administration; always verify applicable federal, state, or contractual benefit terms because those govern in the event of a conflict and may supersede policy statements.

The policy distinguishes surface analgesic stimulators from devices intended to produce muscle contractions. TENS devices deliver transcutaneous currents via surface electrodes to reduce perception of pain, whereas neuromuscular stimulators (e.g., NMES/FES) are intended to directly stimulate motor nerves or muscle to evoke contraction for rehabilitation. Correct device classification is essential for appropriate coverage and billing.

Although trials and reviews report some improvements in muscle strength, endurance, and functional measures in COPD populations and in patients on mechanical ventilation, the evidence does not support replacing formal pulmonary rehabilitation with NMES. Systematic reviews (Cochrane and others) report low to very low quality evidence and inconsistent additive effects; NMES should be considered adjunctive to, not a substitute for, conventional pulmonary rehabilitation programs.

Several devices or indications lack supporting clinical evidence. Examples include manufacturer-specific systems with no published trials (e.g., neo-GEN-Series per Hayes) and modalities with small, low-quality studies such as PES/PEMF. Where published clinical data are absent or insufficient, the policy treats these interventions as unproven and not medically necessary absent strong, peer-reviewed evidence.

NICE guidance recommends that interferential therapy (IFT) should not be offered for knee osteoarthritis, chronic primary pain, or low back pain (with or without sciatica) because evidence of clinical benefit is insufficient or inconsistent.

NICE updated guidance states that PENS, TENS, and IFT should not be offered for low back pain with or without sciatica due to limited, low-quality evidence and lack of sustained clinical benefit beyond short-term effects.

Evidence for percutaneous peripheral nerve stimulation (PNS) is limited and of low-to-very-low quality for many off-label indications (for example, superior cluneal neuralgia or shoulder subluxation post-stroke). Published studies are often small, single-center, or uncontrolled; therefore PNS for these off-label uses lacks sufficient published evidence to support routine coverage.

Pulsed electrical stimulation and pulsed electromagnetic field therapies (PES/PEMF) have inadequate evidence to support routine use for general pain management. Systematic reviews and recent single-center studies report inconsistent results and small sample sizes; routine coverage is not supported without more robust controlled trials.

Scrambler therapy (ST) has been studied in a range of chronic pain conditions, but systematic reviews and guideline panels conclude the evidence is low quality, inconsistent, and insufficient to establish efficacy outside of research settings. Use of ST or translingual stimulation for indications beyond those studied should not be routinely covered absent stronger evidence.

FDA regulatory status is provided for informational context only. FDA approval or clearance alone does not establish medical necessity or guarantee coverage. Coverage decisions require review of the clinical evidence and applicable benefit terms.

The policy references TennCare Medicaid Chapter 1200-13-13-.10: Exclusions; state Medicaid exclusion rules may affect coverage determinations. Verify TennCare exclusions when evaluating claims for Tennessee members, and note that the policy was updated with an amended TennCare reference link in the March 1, 2025 revision.

TennCare Medicaid Chapter 1200-13-13-.10 is cited as a source of state-specific exclusions relevant to coverage determinations. Providers and reviewers should consult that rule when applying this policy for Tennessee Medicaid members.

NMES is considered unproven and not medically necessary for conditions that do not meet the policy's specified covered indications. The policy explicitly lists multiple modalities (e.g., IFT, MENS, PENS/PNT, PENFS, PNS, PSFS/PNFS, PES, restorative neurostimulation, scrambler therapy, translingual stimulation) as unproven/not medically necessary when used outside established, evidence-based indications.

Across several modalities the evidence base is limited, heterogeneous, and often rated low or very low quality by systematic reviewers and HTAs (ECRI, Hayes). These limitations — small sample sizes, single-center designs, inconsistent protocols, and high risk of bias — reduce confidence in observed effects and inform a conservative coverage stance for many newer electrotherapy modalities.

For COPD, systematic reviews report that NMES may improve quadriceps strength and some exercise measures, but evidence quality is low to very low and findings do not consistently translate to improved peak exercise capacity or health-related quality of life. Consequently, there is insufficient evidence to support routine use of NMES alone to improve peak exercise capacity or HRQoL in COPD without concurrent, guideline-recommended pulmonary rehabilitation.

NICE guidance concludes that NMES should not be offered for knee osteoarthritis because electrotherapy studies are inconsistent, small, and provide insufficient evidence of patient-important benefit.

Interferential therapy (IFT/IFC) as a routine adjunct to standard therapy for musculoskeletal conditions has inconsistent evidence of benefit; meta-analyses show variable short-term effects but no clear long-term advantage, supporting a stance that routine use may be not medically necessary without stronger supporting evidence.

Routine use of percutaneous electrical nerve stimulation (PENS) for low back pain or sciatica is not supported by NICE due to insufficient evidence of sustained clinical benefit, and routine authorization should not be granted without clear indication and documentation of conservative therapy failure.

Given the generally low-quality and inconsistent evidence for PNS and PES/PEMF, these therapies are typically considered not medically necessary for most indications in the absence of high-quality supporting data or clearly defined patient selection criteria.

The effectiveness of PES/PEMF for pain is unestablished: systematic reviews and pooled analyses report nonsignificant or inconsistent short-term benefits and call for larger randomized trials before routine clinical adoption.

Scrambler therapy is considered investigational for many chronic pain conditions, including chemotherapy-induced peripheral neuropathy (CIPN). Guideline panels (ASCO, ESMO) and systematic reviews conclude available randomized trials are small, inconsistent, and inadequate to recommend routine use outside clinical trials.

The extract includes TLNS/PoNS evidence summaries and ECRI assessments but does not state an explicit policy-level 'not medically necessary' determination for TLNS in this excerpt. The evidence is described as inconclusive, and further study is recommended; coverage determinations should therefore rely on documented indication, prior therapy, and plan-specific rules.

Applicable Codes and Coding References

Applicable CPT Codes (selected)CPT

0278T	Transcutaneous electrical modulation pain reprocessing (e.g., scrambler therapy), each treatment session (includes placement of electrodes).
0720T	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation.
0783T	Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment.
63650	Percutaneous implantation of neurostimulator electrode array, epidural.
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural.
63663	Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed.
63664	Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed.
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
64555	Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
64596	Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.

1–10 of 13

1/2

Applicable HCPCS / A / L / S Codes (selected)HCPCS

A4438	Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each.
A4543	Supplies for transcutaneous electrical nerve stimulator, for nerves in the auricular region, per month.
A4544	Electrode for external lower extremity nerve stimulator for restless legs syndrome.
A4556	Electrodes (e.g., apnea monitor), per pair.
A4557	Lead wires (e.g., apnea monitor), per pair.
A4593	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, controller.
A4594	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece, each.
A4595	Electrical stimulator supplies, 2 lead, per month, (e.g., TENS, NMES).
E0720	Transcutaneous electrical nerve stimulation (TENS) device, two-lead, localized stimulation.
E0721	Transcutaneous electrical nerve stimulator for nerves in the auricular region.

1–10 of 28

1/3

FES devices verified for HCPCS E0770mixed

E0770 (device verification list)

FES devices CMS PDAC-verified for E0770: NESS L300 and H200 (Bioness); Odstock ODFS Pace FES System (Odstock Medical/Boston Brace); WalkAide (Innovative Neurotronics); Deluxe Digital Electronic Muscle Stimulator (Drive Medical).

Devices and examples mentionedmixed

No codes listed

FES device product codesmixed

GZI	FDA product code referenced for FES devices

NMES device product codesmixed

IPF	FDA product code referenced for NMES devices

IFT device product codesmixed

LIH	FDA product code referenced for Interferential Therapy (IFT) devices

PES device referencesmixed

PES	Product name search reference for pulsed electrical stimulation devices (no single code provided)

Percutaneous PNS/PENS product codesmixed

NHI	FDA product code referenced for PNS and PENS devices

PSFS/PNFS device product codesmixed

PZR	FDA product code referenced for PSFS / PNFS devices (510k)

TENS / MENS / Scrambler device product codesmixed

GZJ	FDA product code referenced for TENS/MENS/Scrambler devices
NUH	Alternate product code referenced for TENS devices
NGX	Alternate product code referenced for TENS devices

Restorative neurostimulation product codesmixed

QLK	Product code referenced for ReActiv8 PMA restorative neurostimulation

Translingual stimulation regulatory referencemixed

PoNS De Novo

De Novo approval reference (March 25, 2021) for the Portable Neuromodulation Stimulator

Coding referencesmixed

HCPCS

Functional Electrical Stimulation (FES) - Coverage and HCPCS Coding referenced (CMS guidance)

Current amplitude distinction — MENS vs TENS

MENS amplitude rangeMicroampere-range currents (sub-sensory) — MENS delivers currents in the microampere (μA) range

TENS amplitude rangeMilliampere-range currents — TENS delivers currents in the milliampere (mA) range producing perceptible paresthesia and often muscle contraction

Relative magnitude1 microampere (μA) = 1/1000 of a milliampere (mA); MENS currents are orders of magnitude lower than TENS

Sensation difference

Prior Authorization, Documentation, and Provider Responsibilities

Prior Authorization

Prior Authorization—Device Implantation and Selected DME

Prior authorization may be required for implantation of restorative neurostimulation devices, implantable peripheral nerve stimulation (PNS) systems, and selected durable medical equipment (DME) related to electrical stimulation therapies. Verify member benefits and obtain any required prior authorization before scheduling device implantation or extended DME rental/supply transactions.

Implanted restorative neurostimulation devices (e.g., ReActiv8) typically require prior authorization and documentation of prior conservative management (e.g., ≥90 days of conservative therapy including physical therapy and medications).
Implantable PNS procedures and percutaneous lead implantations often require prior authorization; short-term external PNS or percutaneous systems may also be subject to plan review.
Selected DME and supply codes (e.g., E0720, E0730, A4593–A4595) may require prior authorization per plan-level DME rules.

Documentation Required

Prior Authorization—Required Indication‑Specific Documentation

Conservative Therapy and Prerequisites

Conservative treatment requirements

Conservative treatment expectation (NMES/TENS): NMES coverage for specified indications is contingent on use as part of a comprehensive rehabilitation program where indicated; TENS medical necessity criteria are determined by InterQual and TennCare Medicaid exclusions, so conservative‑first expectations should be confirmed per those criteria.

Policy emphasizes adjunctive use and defers detailed TENS criteria to InterQual/TennCare.

Prior conservative/rehabilitation therapy implied before NMES standalone; NMES typically supplements standard rehab

Prior conservative/rehabilitation therapy is implied before NMES as standalone; NMES typically supplements standard rehab.

Document prior/concurrent conventional therapy: Document prior or concurrent conventional therapy relevant to the indication (for example: swallowing therapy for dysphagia, pulmonary rehabilitation for COPD, physical therapy for post‑operative or neurologic rehabilitation) demonstrating planned or ongoing standard care alongside NMES.

Trials commonly delivered NMES in addition to standard rehabilitation; documentation should reflect this.

Treatment Frequency, Duration, and Trial Regimens

NMES application regimens — trial examples

THR feasibility RCT exampleUp to 20 NMES sessions delivered over 5 days (minimum 30 minutes per session) reported in a total hip replacement feasibility RCT

Edema prevention trialIn a THR feasibility study NMES was used continuously from post-surgery until discharge with daily circumference measures as outcomes

Home-based programsOther trials evaluated home NMES rehabilitation programs lasting approximately 6–12 weeks as part of post-operative rehab regimens

NMES / CCFES trial regimens

Typical regimen rangeReported trial regimens ranged from daily sessions up to 5–7 days/week for 2–12 weeks

Example session lengthCommon session durations reported: ~20–30 minutes per day in several post-stroke and rehabilitation trials

Imaging and Objective Testing for Authorization

Documentation Required

State NMES regimen and schedule used in trials — include treatment schedule in request

Trials used various NMES application regimens (for example up to 20 sessions over five days for a THR study or home programs lasting 6–12 weeks); include the intended treatment schedule and total course when requesting authorization.

Specify number of sessions, per‑session duration, and total planned weeks consistent with evidence when possible.
Indicate whether therapy will be clinic‑based or home‑based and how adherence will be monitored.

Documentation Required

Imaging not routinely required for NMES outcomes — include when clinically indicated

NMES outcome measurement via imaging is not universally required but may be used when clinically indicated to document objective changes (for example MRI muscle volume in some trials); include imaging results or rationale if used to support benefit.

MRI was used in trials (e.g., Pool et al.) to measure muscle volume after NMES—attach imaging reports if relevant.
Imaging is typically an outcome measure rather than a pre‑requisite; use when it strengthens the clinical justification.

Procedures / Modalities Not Covered or Considered Investigational

Interferential therapy (IFT); Microcurrent electrical nerve stimulation (MENS); Percutaneous electrical nerve stimulation (PENS)/PNT; Percutaneous electrical nerve field stimulation (PENFS); Percutaneous peripheral nerve stimulation (PNS); Peripheral subcutaneous field stimulation (PSFS)/PNFS; Pulsed electrical stimulation (PES); Restorative neurostimulation; Scrambler therapy (ST); and Translingual stimulation (TS) for gait rehabilitation are listed in the policy as modalities considered not covered or not medically necessary in the absence of sufficient evidence.

The policy repeats that multiple electrotherapy modalities lack sufficient evidence and, when requested without supporting clinical documentation and demonstrated medical necessity, are treated as not covered or not medically necessary per the policy's exclusions list.

The policy consistently lists the same set of modalities as unproven/not medically necessary across its not-covered statements; reviewers should apply the specific exclusion language and evidence citations when adjudicating requests.

The repeated modality listing underscores that requests for these therapies require robust peer-reviewed evidence and clear documentation of indication and prior conservative care to be considered for coverage.

Multiple sections of the policy list these modalities as unproven or not medically necessary; consistent application of the exclusion list is expected when evidence is insufficient for the requested indication.

The policy reiterates that listed modalities lacking adequate evidence should be considered investigational or not medically necessary unless new high-quality evidence or specific plan provisions indicate otherwise.

Definitions of Modalities and Terms

Electrical stimulators — general definition

General definitionElectrical stimulators deliver direct, alternating, pulsating and/or pulsed waveform energy for muscle exercise, pain relief, incontinence management, or testing

Control parametersDevices typically permit adjustment of pulse length, pulse repetition frequency, pulse amplitude, and triggering modes

Electrode typesElectrodes may be indwelling, implanted transcutaneous, or surface (cutaneous) depending on modality and indication

NMES — definition and clinical purpose

NMES purposeNeuromuscular electrical stimulation uses transcutaneous currents to evoke muscle contractions to promote reinnervation, prevent disuse atrophy, relax spasms, and restore voluntary control

Application routes

Background, Evidence Summaries and References

Systematic reviews and RCTs summarized in the background and evidence sections informed the coverage considerations and the policy background. These evidence summaries underpin the policy's conservative coverage positions for several modalities and the requirement to document prior conservative care and objective outcomes when requesting device-based therapies.

Evidence-based coverage considerations emphasize limitations in trial design, heterogeneity of stimulation protocols, short follow-up, and small sample sizes across many modalities. Reviewers should weigh these limitations when determining medical necessity and expect detailed documentation of indication, prior therapies, and objective outcome measures for requests involving devices with limited or low-quality evidence.

Guideline-informed conservative care is expected: national guidance including NICE and ACP emphasize noninvasive conservative treatments (exercise, multidisciplinary rehabilitation, self-management) before electrotherapy or implantable neuromodulation. Where guideline recommendations advise against a modality, requests are at increased risk of denial unless compelling, high-quality evidence or plan exceptions exist.

Policy Revision History

2025-03-01RevisionLatest

Updated Coverage Rationale and supporting sections (Description of Services, Clinical Evidence, FDA, and References); updated reference link to TennCare Medicaid Chapter 1200-13-13-.10: Exclusions; archived previous policy version CS036TN.W.

Before submitting authorization requests, verify plan-level requirements and whether UnitedHealthcare will apply InterQual or other third-party criteria. Confirm member-specific federal, state, or contractual coverage rules to determine applicability of this policy and any TennCare exclusions.

Policy Summary

PayerUnitedHealthcare

PolicyElectrical Stimulation for the Treatment of Pain and Muscle Rehabilitation (for Tennessee Only)

Policy CodePolicy CS036TN.X

Change TypeUpdated clinical evidence, device and references

Effective DateMar 1, 2025

Next Review Date

Key ActionObtain prior authorization and document prior conservative therapy and indication-specific objective measures when requesting implantable or extended electrical stimulation therapies.

SourceLink

On This Page

Descriptive; evidence reviews summarized elsewhere.

TENS definition: TENS is surface electrode stimulation intended to reduce pain perception via inhibition of afferent pain impulses and/or endorphin release and is distinct from neuromuscular stimulators used to evoke muscle contraction.

Definition clarifies device classification for coverage and coding.

NMES general evidence positioning: NMES applies transcutaneous currents to evoke muscle contractions for rehabilitation; evidence supports use for disuse atrophy with intact innervation and as an adjunct to standard rehabilitation in multiple musculoskeletal and neurologic conditions, though trials are heterogeneous in protocol and quality.

Summarizes general clinical positioning across indications.

Pediatric cerebral palsy (ankle dorsiflexion NMES): An RCT in children with unilateral spastic CP (n=32) found that 8 weeks of daily NMES-assisted gait increased tibialis anterior muscle volume and dorsiflexion strength with limited carryover after treatment cessation.8-week daily protocol

Functional motor control measures did not differ between groups despite muscle and strength changes.

COPD and ventilated patients: Systematic reviews and RCTs report NMES may improve quadriceps force, endurance, 6‑minute walk distance and may shorten mechanical ventilation time and improve functional independence in select COPD patients, though evidence quality is low-to-very-low and NMES is not a substitute for pulmonary rehabilitation.varied NMES regimens; ICU and ward settings reported

NMES generally considered adjunctive to rehab strategies.

Hospital‑acquired weakness prevention/rehabilitation: Systematic reviews across hospitalized populations (e.g., 42 papers) show small effects on muscle strength and walking performance and moderate effects on muscle size; heterogeneity and risk of bias limit definitive conclusions though NMES is considered promising for preventing or mitigating hospital‑acquired disability.varied durations and frequencies

Adverse experiences reported in a minority of participants.

NICE guidance cited for cautious use.

IFT/IFC for musculoskeletal pain: Meta‑analyses report mixed results with probable short‑term benefit for non‑specific low back pain and some knee OA outcomes, but heterogeneity and small trial sizes limit conclusions; NICE has recommended against routine offering of IFT for several indications.mixed evidence

Systematic reviews and guideline positions summarized.

Device‑specific absence of evidence: Some manufacturer‑specific or marketed systems (e.g., neo‑GEN‑Series) lack peer‑reviewed clinical trial evidence per evidence reviews (Hayes), supporting noncoverage or investigational stance absent new data.no evidence

Hayes EER cited for device‑level evidence gaps.

Evidence supports short‑term/perioperative uses more than sustained chronic benefit.

Coverage decisions should require documented prior therapy failure and objective outcome measures.

Pediatric PENFS prerequisites: PENFS pediatric evidence generally enrolled patients who had failed multiple pharmacologic therapies (often ≥3–4); consider requiring diagnostic criteria (Rome III/IV), documentation of prior therapy failure, baseline validated symptom measures, and planned serial outcome assessments when evaluating medical necessity.

Derived from registry and trial populations in pediatric PENFS studies.

Summarizes device‑level evidence conclusions.

MENS is typically sub-sensory (not felt); TENS is perceptible with tingling/pulsing sensations

Regulatory noteMENS devices are often classified in the same regulatory category as TENS for convenience but operate at distinct amplitudes and mechanisms

Percutaneous PNS treatment durations reported in studies

Common study durationMany percutaneous PNS study protocols left leads in place for approximately 60 days

Typical usage period in trialsLeads commonly remained implanted and active for 8 weeks in randomized trials (reported as 60–64 days) before removal or evaluation

Follow-up after lead removalStudies often included follow-up visits extending months after the 60‑day treatment course to assess durability

Application context60-day percutaneous PNS protocols reported for postoperative persistent pain (e.g., post-TKA) and chronic knee pain studies

Prior authorization requests should include indication-specific clinical documentation. Submit objective baseline measures, prior treatment history, and a clear plan for the proposed stimulation therapy.

Diagnosis and pertinent diagnostic testing or imaging (e.g., evidence of multifidus dysfunction for ReActiv8, nerve localization studies for PNS).
Detailed prior conservative therapy history: duration and specifics of prior physical therapy, medication trials, interventional procedures, and outcomes (document failures or plateaus).
Treatment plan: stimulation parameters, device model, implantation plan (if applicable), trial stimulation details and duration, and planned outcome measures and follow-up schedule.

Prior Authorization

Prior Authorization Recommended for Electrotherapy

Prior authorization is recommended for noninvasive electrotherapy modalities (IFT/IFC/MENS/PENS/TEAS and similar) because evidence is inconsistent across indications; plans may require review to determine medical necessity.

Interferential current (IFC/IFT) and other electrotherapy for knee OA or musculoskeletal pain may be subject to prior authorization due to mixed and often low‑quality evidence (NICE recommendations referenced).
Transcutaneous therapies and limited‑evidence devices (e.g., MENS, TEAS) may require prior authorization when requested for indications lacking strong guideline support.

Prior Authorization

Prior Authorization—Peripheral Nerve Stimulation (PNS)

Implantable and prolonged or extended percutaneous peripheral nerve stimulation (PNS) therapies generally require prior authorization; when requesting authorization, provide comprehensive documentation of conservative therapy failure and indication‑specific evidence.

For implantable PNS or extended percutaneous PNS, include prior noninvasive therapy trials, details of prior interventional treatments, and rationale for escalation to PNS.
Provide trial stimulation results if applicable and objective outcome measures used to determine responder status.

Prior Authorization

Prior Authorization Advised—Restorative Neurostimulation

Prior authorization is advised for restorative neurostimulation and other implanted neuromuscular stimulation devices given limited, variable‑quality evidence and the need to confirm conservative management attempts and appropriateness for the device.

For restorative neurostimulation (e.g., ReActiv8), prior authorization should document ≥90 days of conservative management, prior physical therapy attempts, medication trials, and that the patient is not a candidate for spine surgery.
Include discussion of expected benefits, known limitations of evidence, and plan for device follow‑up and outcome monitoring.

Prior Authorization

Prior Authorization Indicated for Selected Implanted and De Novo Devices

Certain functional electrical stimulation (FES), implanted restorative devices, and De Novo or FDA‑cleared neuromodulation devices may trigger prior authorization requirements; verify device type and intended use in the authorization request.

FDA approval or De Novo clearance is informational only and does not guarantee coverage — include clinical justification that aligns with plan criteria.
When devices are described as implanted neuromuscular stimulators or De Novo products (e.g., PoNS, ReActiv8), indicate the specific product and clinical rationale in the request.

Prior Authorization

Verify Plan‑Level Authorization and Applicable Criteria

Before requesting any authorization, verify plan‑level authorization requirements, state/federal program rules, and contractual benefit terms; use applicable clinical criteria (e.g., InterQual) as directed by the plan.

Check for state Medicaid exclusions or plan‑specific exclusions (e.g., TennCare Chapter 1200‑13‑13‑.10) that may affect coverage.
Document which external criteria or tools (e.g., InterQual) were used to support the authorization request.

Billing Rule

Billing Caveat—Code Inclusion Does Not Guarantee Coverage

Inclusion of a code in this policy is for reference only and does not imply coverage or guarantee payment. Benefits and payment are determined by the member's federal, state, or contractual plan terms.

Ensure benefit determination (medical necessity) is completed per contract prior to assuming coverage for a listed CPT/HCPCS code.
Provider billing should follow plan instructions; listing a code in this policy is not an authorization or payment guarantee.

Billing Rule

Provider Note—Device Classification and Coding Matter

Device classification and accurate procedure coding affect coverage and reimbursement decisions. Distinguish TENS from NMES, FES, PNS, restorative neurostimulation, and other device classes when requesting authorization or submitting claims.

Misclassification (for example, coding a neuromuscular stimulator as a TENS device) can lead to denials; include device model and functional description in the request.
Use the most specific CPT/HCPCS and diagnosis codes available and attach device descriptions or FDA product information when relevant.

Denial Risk

Denial Risk—Evidence Limitations

Evidence limitations and low‑quality or heterogeneous study results increase the risk of authorization denial when documentation is insufficient. When evidence is limited, justify the rationale for use with objective measures and relevant supportive literature.

Trials are frequently small, heterogeneous, or at high risk of bias — address these limitations in the clinical narrative and provide any available high‑quality studies or HTA evaluations (e.g., ECRI, Hayes).
Where guidelines (e.g., NICE, ACP) recommend against or limit use (e.g., IFT for OA or LBP), include clinical justification why the member may be an appropriate exception if applicable.

Denial Risk

Denial Risk—Insufficient Evidence May Trigger Denial

Insufficient or low‑quality evidence for some modalities (e.g., PENS, PENFS, certain PNS indications, NMES for specific conditions) may lead to noncoverage. Authorization requests should directly address guideline conclusions and study limitations.

NICE and other guideline statements that recommend against use (for example, IFT for knee OA or chronic primary pain, and recommendations restricting PENS/PENFS use for LBP) should be considered when anticipating denials.
Supply comparative evidence, responder selection rationale, and documentation of prior therapies when requesting coverage for modalities with limited support.

Documentation Required

Suggested Clinical Documentation Elements

When submitting authorization requests, include suggested clinical documentation elements and objective outcome measures to support medical necessity and monitor response to therapy.

Baseline objective measures (e.g., VAS/NRS pain scores, ODI, WOMAC, 6‑minute walk test, gait/balance scores) and planned post‑therapy assessment timepoints.
Detailed prior treatment history including number and duration of medication trials, physical therapy details, interventional procedures, and response to those therapies.
For trials or temporary/percutaneous stimulation, provide trial parameters, duration, and criteria for proceeding to implantation or continued therapy.

Documentation Required

Clinical Documentation and Outcome Measures

Provide clinical outcome measures and objective functional assessments in authorization submissions and ongoing care documentation to demonstrate medical necessity and treatment response.

Specify baseline and target outcome measures (e.g., >50% pain reduction, improvement in ODI by prespecified points, improvement in walking distance) and timelines for reassessment.
For rehabilitation‑adjunct NMES or PoNS/TLNS, include documentation of adherence to the concurrent physical therapy program and device usage logs where applicable.

Documentation Required

Required Clinical Documentation for Authorization Requests

Required clinical documentation for prior authorization should include the targeted diagnosis, detailed prior treatment history, rationale for the requested modality, and planned monitoring and follow‑up.

Indication description with diagnostic confirmation (imaging, physiologic testing, or specialty evaluation where appropriate).
Comprehensive prior conservative management documentation (PT dates, modalities tried, medication trials and doses, interventional procedures) and duration of each trial.
If requesting implantation, include informed consent discussion, anticipated benefits and risks, and plan for device follow‑up and management of potential complications.

Documentation Required

Documentation Expectations Given Evidence Limitations

Because evidence for many electrotherapies is heterogeneous and short‑term, authorization requests should explain the rationale for use in the specific patient and include objective functional goals and expected timelines for benefit.

Acknowledge evidence limitations (small trials, variable protocols, short follow‑up) and describe why the member is likely to benefit (responder characteristics, refractory status, trial response).
Provide plan for objective reassessment and criteria for discontinuation if goals are not met.

Documentation Required

Recommended Documentation—PENS/PENFS Specifics

When applicable, include details on prior pharmacologic therapy failures, numbers and types of medications tried, diagnostic testing, and trial stimulation results to support requests for PENS, PENFS, and related therapies.

For PENFS/PENFS in pediatric DGBI or functional GI disorders, document prior pharmacologic therapy failures (e.g., failed ≥4 medications) and use validated symptom/function scales (API, NSS, FDI).
For PENS in neuropathic or musculoskeletal conditions, include prior conservative and procedural therapy history and any trial or short‑term response data.

Documentation Required

Device Usage and Therapy Documentation

Device usage data, adherence logs, and concurrent therapy records (e.g., physical therapy sessions for PoNS/TLNS) are important for authorization and ongoing coverage decisions, particularly for adjunctive neuromodulation devices.

Attach device‑logged usage data when available (e.g., PoNS device logs showing adherence).
Report concurrent rehabilitation program attendance and progress notes to demonstrate that device therapy is provided as part of a comprehensive program.

Documentation Required

Supportive Evidence to Include in Documentation

Include supportive external evidence, technology assessments, and guideline summaries to strengthen authorization requests when evidence is limited or mixed.

Reference HTAs and evidence reviews (e.g., Hayes, ECRI) and relevant professional society guidance when available.
If applicable, include pivotal RCT results or long‑term follow‑up data that most closely match the member's clinical scenario.

Prior Authorization

Document Plan‑Specific Requirements and Compliance

Document and confirm any federal, state, or contractual plan‑specific requirements that govern coverage decisions; where conflicts exist, the applicable program terms control.

Verify Medicaid/state plan exclusions or special rules (e.g., TennCare exclusions) prior to authorizing or providing services.
Note that plan language may require use of external criteria (InterQual) or prior authorization pathways specific to the member's contract.

Note

TENS Coverage—State and InterQual References (Tennessee Example)

TENS coverage and exclusions may be affected by state‑level rules (for example, TennCare Chapter 1200‑13‑13‑.10) and by InterQual criteria referenced by the plan; verify these sources when requesting authorization for TENS.

Use InterQual Durable Medical Equipment criteria for TENS where the plan indicates it is used to determine medical necessity.
Check state Medicaid rules (e.g., TennCare) for exclusions that may apply to transcutaneous stimulation devices.

Documentation Required

NMES—Adjunct to Conventional Therapy

NMES is commonly used as an adjunct to conventional rehabilitation; authorization should reflect NMES as part of a comprehensive program rather than as sole therapy unless evidence supports monotherapy.

Document prior or concurrent conventional therapy (targeted PT, gait training, or swallowing therapy) and demonstrate that NMES is being used to augment these programs.
When NMES is used after surgery (e.g., TKA, THR) or in ICU settings, include the rehabilitation protocol and expected short‑ and long‑term outcome measures.

Documentation Required

Adjunctive Use—Documentation Expectations for NMES

Many trials evaluated NMES as an adjunct to standard rehabilitation; authorization should document prior or concurrent conventional therapy and clarify how NMES will be integrated into the rehabilitation plan.

When NMES is requested to improve post‑operative recovery or post‑stroke motor function, provide the timing of NMES initiation relative to surgery or stroke and the concurrent rehabilitation schedule.
Include functional baselines and planned reassessment intervals consistent with published studies.

Step Therapy

Conservative Therapy Expectation Before Advanced Device Therapy

Conservative therapy expectations: document failure, intolerance, or plateau after guideline‑recommended conservative care before requesting advanced neuromodulation or implantable device therapy.

Guideline‑aligned conservative care (e.g., ACP, NICE recommendations) typically includes targeted exercise, multidisciplinary rehabilitation, and pharmacologic management as first‑line steps.
For implantable restorative neurostimulation, document ≥90 days of conservative management including at least one course of physical therapy and medication trials.

Step Therapy

Conservative Therapy Preceding PENFS

For PENFS and similar therapies, document prior conservative care and pharmacologic trials; many published studies included patients who had failed multiple medications or therapies before receiving PENFS.

For pediatric PENFS for DGBI, document prior failed pharmacologic therapies, use validated symptom scales, and show that PENFS is being offered as part of a structured care plan.
Authorization for PENFS should include the number and duration of prior medication trials and outcomes.

Step Therapy

Conservative Care Prerequisite for Implantable Device Consideration

Conservative care is a prerequisite for many implantable and advanced neuromodulation therapies. Provide documentation showing adequate trials of physical therapy, medications, and other noninvasive modalities prior to device implantation requests.

State the duration and specifics of failed conservative care (e.g., PT frequency/dates, medications and doses, interventional procedures attempted).
If conservative care was contraindicated or not feasible, provide supporting clinical rationale and documentation.

Billing Rule

Provider Billing Note—Codes Included for Reference Only

Providers should reference the listed procedure and diagnosis codes when preparing authorization and billing submissions, but remember that code listing is not a coverage guarantee. Attach clinical notes and device details to support correct code usage.

Include the relevant CPT/HCPCS codes and diagnosis codes in the authorization request and attach operative plans or device order forms as appropriate.
If a code is unlisted (e.g., 64999) or a novel device is used, provide detailed operative and device descriptions to support adjudication.

Document prior or concurrent conventional therapy relevant to indication (e.g., swallowing therapy, pulmonary rehab, PT)

Clinical documentation of prior therapy: Provide documentation of prior or concurrent conventional therapies specific to the indication (examples: baseline and planned swallowing therapy sessions and VFSS results for dysphagia; pulmonary rehab enrollment and exercise tolerance for COPD; PT sessions, goals, and objective functional measures for post‑TKA or stroke rehabilitation).

Objective outcome measures cited in trials (e.g., VFSS, IKES, 6MWT, MRI muscle volume) strengthen justification.

Additional conservative requirement nodes (placeholder for specific criteria)

Guideline alignment for conservative therapies: Conservative therapies recommended by guidelines (exercise, multidisciplinary rehabilitation, self‑management) should be attempted prior to electrotherapy modalities where guidelines advise a conservative‑first approach.

ACP and NICE guideline positions cited for conservative‑first expectation.

Conservative therapies should be attempted prior to electrotherapy per guideline recommendations

Conservative‑first expectation: Nonpharmacologic conservative treatments (exercise programs, multidisciplinary rehabilitation, and guideline‑recommended therapies) are expected initial treatments for conditions such as chronic low back pain; electrotherapy may be considered only after appropriate conservative care per guidelines.

Aligns coverage expectations with ACP and NICE guidance.

Documented failure of conservative management is expected for routine authorization consideration.

Documented failure requirement: For modalities with limited evidence (e.g., PENS for LBP, PNS, restorative neurostimulation), document failure of conservative management including appropriate courses of physical therapy and medications prior to routine authorization consideration.

NICE and HTA guidance support requirement for prior conservative care documentation.

Document prior conservative therapy failure (often multiple agents/trials) before PNS/PENFS

PNS/PENFS prior therapy documentation: For PNS and PENFS requests, document prior conservative therapy failures often including multiple pharmacologic trials and noninvasive treatments; many PENFS pediatric study populations had failed ≥3–4 medications prior to enrollment. Provide baseline validated outcome measures and a plan for serial assessment.

Reflects common inclusion criteria in PENFS and PNS studies.

Documentation of prior conservative therapy attempts

Restorative neurostimulation documentation: When restorative neurostimulation (e.g., ReActiv8) is requested, provide documentation of prior conservative management including ≥90 days of medical management and at least one course of physical therapy, patient selection details (multifidus dysfunction), and acknowledgment of device risks and follow‑up plan.>=90 days

Matches inclusion criteria used in pivotal implant trials.

Documented failure of conservative care including physical therapy

ReActiv8 conservative failure threshold: ReActiv8 trial eligibility required >90 days of medical management and at least one attempt of physical therapy prior to implantation; similar documentation of unsuccessful conservative care is reasonable before approving restorative neurostimulation implants.>90 days

Operationalizes restorative neurostimulation trial prerequisites into documentation expectations.

Documented prior targeted physical therapy with plateau in improvement

TLNS/PoNS prior PT plateau: For TLNS/PoNS requests, document prior targeted physical therapy with evidence of plateaued improvement and a plan to continue supervised PT in conjunction with device use, reflecting trial practice where TLNS was delivered as an adjunct to PT.variable (prior PT plateau)

Studies enrolled participants who had plateaued in recovery prior to device use.

Evidence of failed conservative therapy and adjunctive use with supervised PT is implied for these devices.

Adjunctive use expectation: Devices such as restorative neurostimulation and PoNS were studied as adjuncts to supervised physical therapy after conservative care failure; authorization considerations should expect evidence that device use will be adjunctive to ongoing or planned supervised rehabilitation.

Reflects consistency across device trials.

Use of guideline-recommended conservative treatments may be expected prior to advanced neuromodulation interventions.

Guideline‑informed conservative care: Clinical guideline recommendations (e.g., NICE, ACP) emphasize noninvasive conservative therapies before invasive or device‑based neuromodulation; documentation of guideline‑recommended trials and responses should be included in authorization requests for advanced neuromodulation.

Guideline citations inform stepwise conservative expectations.

CCFES specificsCCFES studies included home-based programs with 20-minute daily stimulation plus functional task practice over 12 weeks in some protocols

Home-based patterned stimulation / combined IF and patterned muscle stimulation

Home-based patterned stimulation exampleA multicenter RCT combined interferential (IF) and patterned muscle stimulation in an 8-week home-based program (e.g., 15 min IF + 20 min patterned stimulation per session)

Program durationHome patterned stimulation protocols in trials often ran for multiple weeks (common examples: 6–8 weeks) as part of OA/knee programs

Usage settingRegimens were delivered at home with periodic clinic assessments and patient-reported outcomes

PENS / TEAS / PENFS — study frequency ranges

Frequency variabilityStudy frequencies for PENS/TEAS/PENFS varied widely from single-session protocols up to 16 sessions across trials

Common short-course useMany PENS/TEAS perioperative trials measured outcomes after single or a few sessions within 24–72 hours post-op

Lack of standardizationNo standardized frequency or maximum session limit is established across the literature; protocols differ by indication and study

Percutaneous PNS — leads left in place durations

Leads-in-place durationMany percutaneous PNS study protocols left leads in place for up to 60 days (reported across multiple trials and case series)

Daily use recommendations in trialsSome PNS studies instructed daily device use for multiple hours per day (examples: 6–12 hours/day during the 60-day period)

Post-removal follow-upStudies included follow-up assessments after lead removal to evaluate pain, function, and durability up to 12 months or longer

PENFS application schedules reported in studies

PENFS weekly regimenCommon study approach: weekly PENFS sessions for 4–6 weeks in pediatric and adult trials

Continuous-wear protocolsSome trials used continuous wear regimens of PENFS devices for 5 days per week over 4–6 weeks (e.g., auricular PENFS worn 24 hrs/day during those days)

Variable session countsProtocols ranged by indication from single applications to multi-week series depending on study design

Restorative neurostimulation — follow-up / explant notes

Follow-up and explant observationsRestorative neurostimulation studies report long-term follow-up data (up to 5 years) and note explantation/removal rates in cohorts, but do not specify procedural frequency limits

Typical stimulation protocol post-implantRCT and follow-up studies used programmed stimulation sessions twice daily (e.g., 30 minutes twice daily) after device activation

No procedural frequency limitsLiterature and policy excerpts do not define explicit procedural frequency limits for follow-up visits, programming, or maintenance beyond study protocols

TLNS / PoNS therapy schedules used in studies

TLNS/PoNS regimen exampleTrials delivered TLNS (PoNS) twice daily during an intensive course (example: twice daily for 14 weeks with clinic and home PT components)

RCT schedulesOne RCT used a 5-week in-clinic program followed by home PT with device use monitored; another used 14 weeks total with twice-daily home sessions

Adherence monitoringStudies reported high adherence with device-logged usage (e.g., mean 94% compliance in Ptito et al. when logged by device)

Requests for listed modalities that cite only device marketing claims or limited non-peer-reviewed data will generally not meet medical necessity requirements under this policy.

Where the policy designates a modality as unproven or not medically necessary, prior authorization and rigorous documentation (if allowed by the plan) will typically be required to justify any exception.

The policy's not-covered listings are intended to guide adjudication; plan-level benefit terms, state rules, and InterQual criteria remain determinative for individual coverage decisions.

When modalities are listed as not covered due to insufficient evidence, investigational use or coverage only in research settings may be the appropriate disposition rather than routine clinical coverage.

The policy emphasizes that FDA regulatory status is informational and does not by itself establish coverage. Reviewers must evaluate the clinical evidence and confirm applicable benefit plan terms before authorizing services.

The policy repeats the list of modalities considered not medically necessary in multiple sections to ensure clarity for adjudicators: IFT, MENS, PENS/PNT, PENFS, PNS, PSFS/PNFS, PES, restorative neurostimulation, scrambler therapy, and translingual stimulation among others — unless specific high-quality evidence or plan rules permit coverage.

Applied via surface electrodes to muscle groups or over motor nerves when nerve supply is intact

Clinical usesUsed in rehabilitation contexts including post-operative recovery, stroke/post-stroke motor recovery, cerebral palsy, and ICU-acquired weakness

Interferential Therapy (IFT) — definition

IFT mechanismInterferential therapy delivers two medium-frequency pulsed currents that intersect to produce a low-frequency resultant current intended to penetrate deeper tissues

Proposed effectTheorized benefits include endorphin release, increased blood flow, and reduced edema via parasympathetic stimulation

Evidence noteStudies are heterogeneous and of variable quality; systematic reviews call for more robust trials to establish efficacy

MENS — definition

MENS definitionMicrocurrent Electrical Nerve Stimulation (MENS) delivers microampere-range currents intended for pain relief and wound healing; stimuli are typically sub-sensory

TerminologyAlso referred to as micro electrical therapy (MET) or micro electrical neuro-stimulation; regulatory classification may overlap with TENS

SensationMENS currents are generally not perceived by the user (sub-sensory), unlike TENS which is perceptible

Pulsed Electrical Stimulation (PES) / PEMF — definition

PES definitionPulsed Electrical Stimulation (PES) is hypothesized to facilitate bone and cartilage repair and alter inflammatory cell function via induced electrical fields

Clinical evidenceCurrent evidence for PES/PEMF in chronic pain is insufficient; more robust RCTs are needed to establish efficacy

Proposed mechanismsMay affect chondrocyte/osteoblast activity and intracellular signaling (cAMP, DNA synthesis) via electrostatic/electrodynamic fields

Restorative Neurostimulation — definition

Restorative neurostimulation conceptImplantable restorative neurostimulation targets the lumbar multifidus via leads near the medial branch of the dorsal ramus to rehabilitate neuromuscular control in chronic mechanical low back pain

Device exampleReActiv8 Implantable Neurostimulation System is an example and received PMA for bilateral L2 medial branch stimulation

Intended useUsed as rehabilitative therapy for impaired multifidus control in adults who have failed conservative care and are not candidates for spine surgery

Scrambler Therapy (ST) — definition

Scrambler Therapy definitionScrambler Therapy (ST) is a noninvasive transdermal treatment providing variable, nonlinear waveforms via skin electrodes to present 'non-pain' information to painful dermatomes

Typical protocolCommon protocols described: 30–50 minute sessions over ~10 working days in many trials

Evidence noteSystematic reviews conclude insufficient high-quality evidence to confirm efficacy for many chronic pain conditions

TENS — definition

TENS definitionTranscutaneous Electrical Nerve Stimulation (TENS) delivers surface electrode currents to reduce pain perception by inhibiting afferent pain impulses and/or stimulating endorphin release

Distinction from NMESTENS is distinct from neuromuscular stimulators — devices intended to directly stimulate muscle/motor nerves are not TENS

Typical effectProduces perceptible paresthesia and sometimes muscle pulsing depending on amplitude and lead placement

Translingual Stimulation (TLS/PoNS) — definition

TLS / PoNS definitionTranslingual stimulation (TLS/PoNS/TLNS) delivers portable neuromodulation to the tongue surface combined with physical therapy to enhance neuroplasticity and gait/balance recovery

Regulatory statusPoNS received De Novo approval (March 25, 2021) for short-term treatment of gait deficit due to mild-to-moderate MS as adjunct to supervised exercise

Intended adjunctive useStudied as an adjunct to targeted PT programs in mmTBI, MS, and other neurologic conditions; trials report device-logged adherence

NMES / FES / CCFES — definitions

NMES for rehab definitionNMES applied to muscles or nerves to evoke muscle contraction to restore motor function (used for gait, upper/lower extremity recovery, swallowing therapy)

FES relationFunctional electrical stimulation (FES) is a subset of NMES used to restore functional movements such as ambulation or hand opening

CCFES definitionContralaterally controlled functional electrical stimulation (CCFES) uses movements of the unaffected limb to control stimulation of the affected limb for functional tasks